Do Mushrooms Show Up on a Drug Test?

Mushrooms do not show up on a drug test in most standard situations. Psilocybin and its active metabolite psilocin are not included in the standard 5-panel, 10-panel, or 12-panel screens used by most employers.

Detection requires a specialized assay that specifically targets psilocin, usually LC-MS/MS or GC-MS. These tests cost more and are ordered rarely, mostly in forensic, clinical toxicology, and certain military settings.

Timing matters more than test sensitivity. Psilocin clears the body quickly, with a half-life of roughly two to three hours, so even specialized urine testing detects it for only about a day after use.

Key Takeaways

• •Psilocybin does not appear on standard 5-panel, 10-panel, or 12-panel drug tests, because psilocin is not an authorized analyte on those screens.
• •The federal Department of Transportation 5-panel screens only marijuana, cocaine, amphetamines, opioids, and phencyclidine, so CDL drivers are not tested for psilocybin.
• •Psilocin has an elimination half-life of roughly two to three hours, and urine concentrations typically fall below the limit of quantitation about 24 hours after a dose.
• •As of October 1, 2025, the U.S. Department of Defense added psilocin to its military drug testing panel.
• •In 2023, 3.1 percent of Americans aged 12 and older reported past-year hallucinogen use, rising to 6.7 percent among adults aged 18 to 25.

What Drug Tests Actually Look For in Magic Mushrooms?

Psilocybin is a prodrug, meaning it is inactive until the body converts it. Enzymes rapidly strip a phosphate group from psilocybin, producing psilocin. Psilocin is the compound responsible for psychedelic effects, and it is the compound laboratories target.

A laboratory searching for evidence of mushroom use does not look for psilocybin in blood or hair. Intact psilocybin is largely absent from those samples because conversion happens so quickly after ingestion.

The liver then processes psilocin further. Most of it becomes psilocin glucuronide, an inactive conjugate, while a smaller portion converts to 4-hydroxyindole-3-acetic acid. Both metabolites leave the body primarily through urine, along with a small fraction of free psilocin.

Do Standard Drug Tests Detect Psilocybin?

Standard workplace panels do not include psilocin. The federally mandated screen, often called the SAMHSA-5, covers marijuana, cocaine, amphetamines, opioids, and phencyclidine. MDMA is captured under the amphetamine class, and fentanyl was added effective July 7, 2025.

Expanded commercial panels add more substances without adding psilocin. A standard 10-panel test adds barbiturates, benzodiazepines, methadone, methaqualone, and oxycodone. A 12-panel test adds further analytes, yet psilocybin mushrooms remain outside its scope.

Immunoassay screening relies on antibodies developed for specific drug classes with high prevalence in workplace populations. Psilocin requires a separate, targeted method, which laboratories do not run unless a client specifically requests it.

How Long Does Psilocybin Stay in the System?

Effects begin roughly 20 to 40 minutes after ingestion, and plasma concentrations peak at about two hours. Psilocin's elimination half-life sits near two to three hours, one of the shortest among commonly discussed recreational substances.

Research found that only about 1.5 to 3.4 percent of a dose is excreted as free psilocin within 24 hours, alongside roughly 20 percent as psilocin glucuronide. Most people clear measurable psilocin within a single day. Heavier or repeated dosing can extend that slightly, but not to the multi-day windows associated with cannabis or benzodiazepines.

Psilocybin Detection Windows by Test Type

Urine Testing

Urine offers the most reliable specialized detection route. Controlled research measured peak psilocin concentrations up to 870 micrograms per liter within two to four hours after dosing, with levels falling to the 10 microgram limit of quantitation by 24 hours.

Blood Testing

Blood testing captures a narrower window because plasma concentrations decline steeply after the two-hour peak. Detection generally becomes impractical around six hours post-dose. Blood collection is also invasive, so it appears mainly in impairment investigations and clinical research settings.

Saliva Testing

No validated saliva detection window exists for psilocin. The widely repeated "up to 24 hours" figure has no traceable primary source. Psilocin is chemically unstable in oral fluid, which undermines the reliability of any oral fluid result for this substance.

Hair Follicle Testing

Hair testing for psilocin is technically possible but difficult to interpret. Forensic researchers detected psilocin in hair at only 2.5 to 5.4 picograms per milligram in one repeat user, concentrations sitting near the detection limit of the instrument.

Specialized and Situational Drug Testing for Hallucinogens

DOT Drug Tests and CDL Drivers

Department of Transportation testing follows a fixed federal panel. Under 49 CFR Part 40, the required classes are marijuana, cocaine, amphetamines, phencyclidine, and opioids. Commercial drivers tested under Part 382 face the same five classes, without psilocybin.

Employers may run separate non-DOT screening under their own company authority. Those tests are distinct from the federal regimen and may include additional substances, though hallucinogen panels remain uncommon even in that context.

Military Drug Testing

Military policy changed recently. The Department of Defense added psilocin to its Drug Demand Reduction Program panel effective October 1, 2025, citing risks to security, military fitness, readiness, and good order and discipline.

Rollout prioritizes probable-cause, consent, and command-directed specimens before expanding into broader random testing as laboratory capacity develops. Commanders previously held authority to order expanded testing, but psilocin now enters routine laboratory processing rather than requiring a special request.

Probation and Court-Ordered Testing

Probation programs typically use 5-panel or 10-panel screens that omit psilocin. Courts and probation officers can, however, order expanded or substance-specific testing. That happens most often after hallucinogen-related charges or when reasonable suspicion exists.

Can Mushrooms Cause a False Positive?

Psilocin shows minimal cross-reactivity on standard immunoassays. Validation work on a psilocin-specific immunoassay recorded under 0.01 percent cross-reactivity with serotonin, tryptophan, and tyrosine, and between 0.01 and 2 percent with THC, cocaine, morphine, and amphetamine.

Culinary and functional mushrooms cannot trigger a positive result either. Portobello, shiitake, lion's mane, reishi, chaga, and mushroom coffee products contain no psilocybin, so they produce no psilocin and no detectable metabolite.

Mushrooms purchased informally are sometimes adulterated with other substances, including phencyclidine. An adulterant can produce a positive result on a standard panel even though psilocybin itself would not.

What Affects How Long Mushrooms Stay Detectable?

Dose is the strongest variable. Larger amounts produce higher peak concentrations and take marginally longer to fall below laboratory cutoffs. Frequency of use compounds this effect, particularly for hair analysis where repeated exposure accumulates trace material.

Individual biology also contributes. Liver enzyme activity, including CYP2D6 and CYP3A4 pathways, influences conversion speed. Kidney function affects excretion rate, while hydration status changes urine concentration and can shift a borderline result either direction.

Test timing outweighs nearly all of these factors. Because the detection window is so narrow, the interval between use and specimen collection determines the outcome far more than metabolism or body composition.

Federal and State Legal Status of Psilocybin

Psilocybin and psilocin remain Schedule I substances under the federal Controlled Substances Act. That classification reflects a determination of high abuse potential, no currently accepted medical use, and a lack of accepted safety under medical supervision.

Several states have created regulated pathways. Oregon and Colorado operate licensed supervised service center programs. New Mexico enacted a medical psilocybin framework in 2025, and New Jersey approved a hospital-based behavioral health pilot program in January 2026.

These programs do not create retail markets, and decriminalization at the city level is not legalization. Federal Schedule I status still governs nationwide, which continues to shape employer policy and court-ordered testing decisions.

Finding the Right Level of Support at Archangel Centers

Repeated psilocybin use rarely happens in isolation. It frequently appears alongside alcohol, cannabis, or stimulant use, and often alongside untreated anxiety or depression that the substance temporarily quiets.

Archangel Centers addresses those layers together across a connected continuum. Partial Care runs Monday through Saturday for people who need daily structure. Intensive outpatient meets three or five days weekly, and outpatient sessions support people maintaining stability over time.

Programming combines CBT, DBT, narrative therapy, and both 12-step and SMART Recovery facilitation, so clients are not limited to a single recovery framework. Individual therapy happens weekly in Partial Care and every two weeks in intensive outpatient, with dual diagnosis care integrated throughout.